Scotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the 12 best dividend stocks in the Dow Jones according to hedge funds [1] - Scotiabank has raised its price target for Johnson & Johnson from $230 to $265 following strong quarterly results, maintaining an Outperform rating [2] Group 1: Patent Management and Sales Outlook - Johnson & Johnson is effectively managing patent pressures, with products like Stelara facing biosimilar competition and generics expected for Opsumit in the US by the second half of 2026 [3] - The company anticipates a steady outlook, projecting 2026 sales growth of approximately 6.7% and adjusted EPS growth of about 6.9% at the midpoint of guidance [3] Group 2: Portfolio Strength and Growth - By the end of 2025, Johnson & Johnson will have 28 platforms, each generating at least $1 billion annually, with new additions including the Shockwave intravascular lithotripsy device and cancer therapy Carvykti [4] - Thirteen brands within the portfolio are experiencing double-digit growth rates, contributing to a balanced business model [4] Group 3: Pipeline Developments - Johnson & Johnson plans to seek regulatory approvals for five drugs this year and intends to file for two additional drugs, with results from at least 10 Phase 3 trials expected [5] - The company operates across the healthcare sector, focusing on the research, development, manufacturing, and sale of a wide range of medical products globally [5]